Novartis and Pfizer have announced an agreement that aims to advance the treatment of non-alcoholic steatohepatitis (NASH), a form of liver disease.
The clinical development pact will include a study combining Novartis’ Farnesoid X receptor agonist tropifexor with one or more Pfizer compounds for the treatment of NASH, including an acetyl CoA-carboxylase inhibitor (PF-05221304), a diacylglycerol O-acyltransferase 2 inhibitor (PF-06865571), and a ketohexokinase inhibitor (PF-06835919).
There are currently no options available to treat NASH, which the firms note presents “a high unmet patient need” as it affects up to 6.5% of the population worldwide and is largely asymptomatic.
As fat builds up in the liver, it can trigger a cycle of chronic inflammation and liver scarring (fibrosis) which, over time, can cause cirrhosis, liver failure and death.
“Liver diseases, including NASH, are multifaceted with various factors that contribute to the progression of the disease. This makes them difficult to treat with a single compound,” said Eric Hughes, Global Development Unit head, Immunology, Hepatology and Dermatology.
“We want to collaborate with multiple partners to drive the science and understanding of how to treat non-viral liver diseases. Targeting different pathways in NASH with a broad array of therapies is an essential strategy to bring the best treatments to patients.”
Further details and of the deal were not disclosed.
By Selina McKee
Source: Pharma Times
The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.
Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.
Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.
